Search


	Podcast:		The Bio Report
	Episode:		A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response
	Category:		Business
	Duration:		00:29:54
	Publish Date:		2021-02-25 09:00:28
	Description:		Phosplatin Therapeutics is developing a class of small molecule cancer therapies designed to avoid the problems of drug resistance and toxicity associated with chemotherapies. The company’s lead experimental therapy is a first-in-class small molecule that promotes immunogenic cell death, a type of cell death that elicits an immune response. We spoke to Matthew Price, co-founder, executive vice president, and chief operating officer of Phosplatin, about the company’s lead therapy, its multiple mechanisms of action, and why it may have benefit in a broad range of cancers.
	Total Play:		0

Some more Podcasts by Levine Media Group

600+ Episodes

The Bio Repo ..